Table 1 Baseline characteristics of patients enrolled in COAST-X
PBO (N = 105) | IXE Q4W (N = 96) | IXE Q2W (N = 102) | Total (N = 303) | |
|---|---|---|---|---|
Age, years | 39.9 (12.4) | 40.9 (14.5) | 40.0 (12.0) | 40.3 (12.9) |
Male, n (%) | 44 (41.9) | 50 (52.1) | 49 (48.0) | 143 (47.2) |
Weight, kg | 75.8 (18.4) | 79.5 (16.5) | 77.3 (16.6) | 77.5 (17.2) |
Duration of nr-axSpA symptoms, years | 10.1 (8.3) | 11.3 (10.7) | 10.6 (10.1) | 10.7 (9.7) |
Time since nr-axSpA diagnosis, years | 3.1 (4.5) | 4.2 (5.5) | 3.4 (4.6) | 3.6 (4.9) |
CRP, mg/L | 14.3 (24.4) | 12.4 (18.0) | 12.1 (17.8) | 12.9 (20.4) |
Screening MRI/CRP status, n (%) | ||||
Positive MRI and elevated CRP | 38 (36.2) | 30 (31.3) | 39 (38.2) | 107 (35.3) |
Positive MRI and nonelevated CRP | 40 (38.1) | 36 (37.5) | 34 (33.3) | 110 (36.3) |
Negative MRI and elevated CRP | 26 (24.8) | 30 (31.3) | 28 (27.5) | 84 (27.7) |
Therapy, n (%) | ||||
Current csDMARD use, including MTX | 36 (34.3) | 40 (41.7) | 42 (41.2) | 118 (38.9) |
Current MTX use | 17 (16.2) | 17 (17.7) | 15 (14.7) | 49 (16.2) |
Current NSAID/COX-2 inhibitor use | 96 (91.4) | 81 (84.4) | 95 (93.1) | 272 (89.8) |
ASDAS-CRP | 3.8 (0.9) | 3.8 (0.8) | 3.9 (0.8) | 3.8 (0.8) |
BASDAI | 7.2 (1.5) | 7.0 (1.5) | 7.3 (1.3) | 7.2 (1.4) |
Sleep (JSEQ) | 9.4 (5.6) | 9.4 (5.3) | 10.4 (5.3) | 9.7 (5.4) |
Reported part- or full-time work, n (%) | 69 (65.7) | 61 (63.5) | 66 (64.7) | 196 (64.7) |
Work productivity (WPAI-SpA) | ||||
Absenteeism | 15.6 (26.8)a | 12.1 (27.0)b | 16.1 (26.5)c | 14.7 (26.7)d |
Presenteeism* | 62.1 (18.7)e | 50.2 (22.3)f | 56.3 (24.8)g | 56.7 (22.4)h |
Overall work impairment* | 65.6 (20.2)e | 51.9 (22.8)f | 59.3 (26.4)g | 59.5 (23.7)h |
Activity impairment | 66.4 (20.4) | 63.3 (21.5) | 66.1 (20.7) | 65.3 (20.8) |